STATE-OF-THE-ART PAPER
Vascular Endothelial Growth FactorsBiology and Current Status of Clinical Applications in Cardiovascular Medicine
Seppo Ylä-Herttuala, MD, PhD, FESC*, , ,1,*,
Tuomas T. Rissanen, MD, PhD*,1,
Ismo Vajanto, MD and
Juha Hartikainen, MD, PhD
* Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute, Kuopio University, Kuopio, Finland
Department of Medicine, Kuopio University and Kuopio University Hospital, Kuopio, Finland
Department of Surgery, Kuopio University and Kuopio University Hospital, Kuopio, Finland
Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland.
Manuscript received April 17, 2006;
revised manuscript received September 22, 2006,
accepted September 27, 2006.
* Address for correspondence: Dr. Seppo Ylä-Herttuala, Professor of Molecular Medicine, Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, P.O. Box 1627, FIN-70211 Kuopio, Finland. (Email: seppo.ylaherttuala{at}uku.fi).
Members of the vascular endothelial growth factor (VEGF) family are among the most powerful modulators of vascular biology. They regulate vasculogenesis, angiogenesis, and vascular maintenance during embryogenesis and in adults. Because of their profound effects on blood vessels, VEGFs have received much attention regarding their potential therapeutic use in cardiovascular medicine, especially for therapeutic vascular growth in myocardial and peripheral ischemia. However, completed randomized controlled VEGF trials have not provided convincing evidence of clinical efficacy. On the other hand, recent preclinical proangiogenic VEGF studies have given insight, and anti-VEGF studies have shown that the disturbance of vascular homeostasis by blocking VEGF-A may lead to endothelial dysfunction and adverse vascular effects. Excess VEGF-A may contribute to neovascularization of atherosclerotic lesions but, currently, there is no evidence that transient overexpression by gene transfer could lead to plaque destabilization. Here, we review the biology and effects of VEGFs as well as the current status of clinical applications and future perspectives of the therapeutic use of VEGFs in cardiovascular medicine.
|
Abbreviations and Acronyms
| | CAD = coronary artery disease | | CCS = Canadian Cardiovascular Society | | CLI = critical limb ischemia | | EC = endothelial cell | | NO = nitric oxide | | PAD = peripheral arterial disease | | PlGF = placental growth factor | | pu = particle units | | SMC = smooth muscle cell | | VEGF = vascular endothelial growth factor | | VEGFR = VEGF receptor |
|
This article has been cited by other articles:
|
|
|
|
 
Q. Guo, J. J. Carrero, X. Yu, P. Barany, A. R. Qureshi, M. Eriksson, B. Anderstam, M. Chmielewski, O. Heimburger, P. Stenvinkel, et al.
Associations of VEGF and its receptors sVEGFR-1 and -2 with cardiovascular disease and survival in prevalent haemodialysis patients
Nephrol. Dial. Transplant.,
November 1, 2009;
24(11):
3468 - 3473.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Bruegmann, R. Gruemmer, J. Neulen, and K. Motejlek
Regulation of soluble vascular endothelial growth factor receptor 1 secretion from human endothelial cells by tissue inhibitor of metalloproteinase 1
Mol. Hum. Reprod.,
November 1, 2009;
15(11):
749 - 756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Zisa, A. Shabbir, M. Mastri, G. Suzuki, and T. Lee
Intramuscular VEGF repairs the failing heart: role of host-derived growth factors and mobilization of progenitor cells
Am J Physiol Regulatory Integrative Comp Physiol,
November 1, 2009;
297(5):
R1503 - R1515.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Gupta, J. Tongers, and D. W. Losordo
Human Studies of Angiogenic Gene Therapy
Circ. Res.,
October 9, 2009;
105(8):
724 - 736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Thangarajah, D. Yao, E. I. Chang, Y. Shi, L. Jazayeri, I. N. Vial, R. D. Galiano, X.-L. Du, R. Grogan, M. G. Galvez, et al.
The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues
PNAS,
August 11, 2009;
106(32):
13505 - 13510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Zhang, K. Sun, Y. Zhen, D. Wang, Y. Wang, J. Chen, J. Xu, F. B. Hu, and R. Hui
VEGF Receptor-2 Variants Are Associated With Susceptibility to Stroke and Recurrence
Stroke,
August 1, 2009;
40(8):
2720 - 2726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. T. H. Wu, M. O. Stefanini, F. Mac Gabhann, C. D. Kontos, B. H. Annex, and A. S. Popel
Computational kinetic model of VEGF trapping by soluble VEGF receptor-1: effects of transendothelial and lymphatic macromolecular transport
Physiol Genomics,
June 10, 2009;
38(1):
29 - 41.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Lieb, R. Safa, E. J. Benjamin, V. Xanthakis, X. Yin, L. M. Sullivan, M. G. Larson, H. M. Smith, J. A. Vita, G. F. Mitchell, et al.
Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function
Eur. Heart J.,
May 1, 2009;
30(9):
1121 - 1127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Zhang, L. Ding, Y. Zhao, W. Sun, B. Chen, H. Lin, X. Wang, L. Zhang, B. Xu, and J. Dai
Collagen-Targeting Vascular Endothelial Growth Factor Improves Cardiac Performance After Myocardial Infarction
Circulation,
April 7, 2009;
119(13):
1776 - 1784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Lahteenvuo, M. T. Lahteenvuo, A. Kivela, C. Rosenlew, A. Falkevall, J. Klar, T. Heikura, T. T. Rissanen, E. Vahakangas, P. Korpisalo, et al.
Vascular Endothelial Growth Factor-B Induces Myocardium-Specific Angiogenesis and Arteriogenesis via Vascular Endothelial Growth Factor Receptor-1- and Neuropilin Receptor-1-Dependent Mechanisms
Circulation,
February 17, 2009;
119(6):
845 - 856.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E.M. Mullane, Z. Dong, C.M. Sedgley, J.C.-C. Hu, T.M. Botero, G.R. Holland, and J.E. Nor
Effects of VEGF and FGF2 on the Revascularization of Severed Human Dental Pulps
Journal of Dental Research,
December 1, 2008;
87(12):
1144 - 1148.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Korpisalo, T. T. Rissanen, T. Bengtsson, T. Liimatainen, S. Laidinen, H. Karvinen, J. E. Markkanen, O. H. Grohn, and S. Yla-Herttuala
Therapeutic angiogenesis with placental growth factor improves exercise tolerance of ischaemic rabbit hindlimbs
Cardiovasc Res,
November 1, 2008;
80(2):
263 - 270.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Chen, R. Kerkela, and T. Force
Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
Circulation,
July 1, 2008;
118(1):
84 - 95.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Heiss, N. Amabile, A. C. Lee, W. M. Real, S. F. Schick, D. Lao, M. L. Wong, S. Jahn, F. S. Angeli, P. Minasi, et al.
Brief Secondhand Smoke Exposure Depresses Endothelial Progenitor Cells Activity and Endothelial Function: Sustained Vascular Injury and Blunted Nitric Oxide Production
J. Am. Coll. Cardiol.,
May 6, 2008;
51(18):
1760 - 1771.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. M.S. van den Akker, V. Caolo, L. J. Wisse, P. P.W.M. Peters, R. E. Poelmann, P. Carmeliet, D. G.M. Molin, and A. C. Gittenberger-de Groot
Developmental coronary maturation is disturbed by aberrant cardiac vascular endothelial growth factor expression and Notch signalling
Cardiovasc Res,
May 1, 2008;
78(2):
366 - 375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G. Saueressig, A. M. Neto, E. A.F. Fortis, D. Westphal, M. I.A. Edelweiss, L. Meurer, and U. Matte
Vascular endothelial growth factor gene therapy induces early re-establishment of canine bronchial circulation
Eur. J. Cardiothorac. Surg.,
April 1, 2008;
33(4):
717 - 722.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. T. Rissanen, P. Korpisalo, H. Karvinen, T. Liimatainen, S. Laidinen, O. H. Grohn, and S. Yla-Herttuala
High-resolution ultrasound perfusion imaging of therapeutic angiogenesis.
J. Am. Coll. Cardiol. Img.,
January 1, 2008;
1(1):
83 - 91.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. L. Johnson, L. Schofield, T. Donahay, M. Bouchard, A. Poppas, and R. Haubner
Radiolabeled RGD Peptides to Image Angiogenesis in Swine Model of Hibernating Myocardium.
J. Am. Coll. Cardiol. Img.,
January 1, 2008;
1:
500 - 510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Toutouzas, J. Karabelas, S. Vaina, and C. Stefanadis
Antivascular Endothelial Growth Factor-A Treatment: New Perspectives for High-Risk Plaque Stabilization
J. Am. Coll. Cardiol.,
July 10, 2007;
50(2):
186 - 186.
[Full Text]
[PDF]
|
|
|
|
